Adherence and patients' attitudes to oral anticancer drugs: A prospective series of 201 patients focusing on targeted therapies

Oncology (Switzerland)

Volumn 88, Issue 1, 2015, Pages 1-8

  Barthélémy, Philippe ^a   Asmane De La Porte, Irène ^a   Meyer, Nicolas ^a   Duclos, Brigitte ^a   Serra, Sebastian ^a   Dourthe, Louis Marie ^a   Amé, Shanti ^a   Litique, Valère ^c   Giron, Cathy ^a   Goldbarg, Veronica ^a   Fornecker, Luc ^a   Quoix, Elisabeth ^b   Kurtz, Jean Emmanuel ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^c CHG   (France)

Author keywords

Adherence; Cancer; Oral chemotherapy; Targeted therapies

Indexed keywords

ABIRATERONE; ANASTROZOLE; ANTINEOPLASTIC AGENT; AXITINIB; BICALUTAMIDE; CAPECITABINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DASATINIB; ERLOTINIB; ESTRAMUSTINE; EVEROLIMUS; EXEMESTANE; HYDROCORTISONE; IMATINIB; LAPATINIB; LENALIDOMIDE; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MEGESTROL; NAVELBINE; NILOTINIB; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HEALTH SURVEY; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CANCER; LOW DRUG DOSE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MEDICATION COMPLIANCE; METASTASIS; MOLECULARLY TARGETED THERAPY; MOTIVATION; MYELOMA; OVARY CANCER; PATIENT COMPLIANCE; PERCEPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; QUESTIONNAIRE; SIDE EFFECT; SOLID TUMOR; STOMACH CANCER; TREATMENT DURATION; AGE; ATTITUDE; MIDDLE AGED; NEOPLASMS; ORAL DRUG ADMINISTRATION; VERY ELDERLY;

ADMINISTRATION, ORAL; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ATTITUDE; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROSPECTIVE STUDIES; QUESTIONNAIRES;

EID: 84925286434     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000366226     Document Type: Article

References (16)

1. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, et al: Medication compliance and persistence: terminology and definitions. Value Health 2008; 11: 44-47
2. Ruddy K, Mayer E, Partridge A: Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 2009; 59: 56-66
3. Partridge AH, Avorn J, Wang PS, Winer EP: Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002; 94: 652-661
4. Font R, Espinas JA, Gil-Gil M, Barnadas A, Ojeda B, Tusquets I, et al: Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain. Br J Cancer 2012; 107: 1249-1256
5. Gater A, Heron L, Abetz-Webb L, Coombs J, Simmons J, Guilhot F, et al: Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia. Leuk Res 2012; 36: 817-825
6. Ibrahim AR, Eliasson L, Apperley JF, Milojkovic D, Bua M, Szydlo R, et al: Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 2011; 117: 3733-3736
7. Al-Barrak J, Cheung WY: Adherence to imatinib therapy in gastrointestinal stromal tumors and chronic myeloid leukemia. Support Care Cancer 2013; 21: 2351-2357
8. Wu EQ, Johnson S, Beaulieu N, Arana M, Bollu V, Guo A, et al: Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin 2010; 26: 61-69
9. Darkow T, Henk HJ, Thomas SK, Feng W, Baladi JF, Goldberg GA, et al: Treatment interruptions and nonadherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 2007; 25: 481-496
10. Simons S, Ringsdorf S, Braun M, Mey UJ, Schwindt PF, Ko YD, et al: Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care. Support Care Cancer 2011; 19: 1009-1018
11. Kirk MC, Hudis CA: Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer. Clin Breast Cancer 2008; 8: 155-161
12. Wood L: A review on adherence management in patients on oral cancer therapies. Eur J Oncol Nurs 2012; 16: 432-438
13. Streeter SB, Schwartzberg L, Husain N, Johnsrud M: Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. J Oncol Pract 2011; 7: 46s-51s
14. Partridge AH, Archer L, Kornblith AB, Gralow J, Grenier D, Perez E, et al: Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol 2010; 28: 2418-2422
15. Krolop L, Ko YD, Schwindt PF, Schumacher C, Fimmers R, Jaehde U: Adherence management for patients with cancer taking capecitabine: a prospective two-arm cohort study. BMJ Open 2013; 3: e003139
16. Mathes T, Antoine SL, Pieper D, Eikermann M: Adherence enhancing interventions for oral anticancer agents: a systematic review. Cancer Treat Rev 2014; 40: 102-108